SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Gerdts J)
 

Sökning: WFRF:(Gerdts J) > Sex-related differe...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003516naa a2200553 4500
001oai:gup.ub.gu.se/56086
003SwePub
008240910s2004 | |||||||||||000 ||eng|
024a https://gup.ub.gu.se/publication/560862 URI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Bella, J. N.4 aut
2451 0a Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study
264 1c 2004
520 a While left ventricular (LV) structure and function differ between hypertensive women and men, it remains unclear whether sex affects regression of LV hypertrophy with antihypertensive treatment. We analysed paired echocardiograms in 500 men and 347 women enrolled in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study at baseline and after 12 months of antihypertensive treatment with either losartan or atenolol. At enrollment, 177 women and 242 men were randomized to losartan-based treatment and 161 women and 247 men were randomized to atenolol-based treatment (sex difference=NS). After 12 months of antihypertensive treatment, blood pressure was lowered similarly in women (152/83 from 174/97 mmHg) and men (149/85 from 173/99 mmHg; both P<0.001, sex difference=NS), without significant change in body weight in either sex. Cardiac output and pulse pressure/stroke volume were equivalently reduced in both sexes (-0.2 vs -0.1 l/min and both -0.20 mmHg/ml/m(2), respectively; both P=NS). Absolute LV mass change after 12 months of antihypertensive treatment was greater in men than in women (-30 vs -24 g, P=0.01). However, after adjusting for baseline LV mass and randomized study treatment, LV mass reduction was greater in women than in men (-33 vs -23 g, P=0.001). LV mass regression was greater in women, by 8.0+/-2.8 g, after adjusting for baseline LV mass and randomized study treatment. After consideration of baseline LV mass and randomized study treatment, antihypertensive treatment regressed LV hypertrophy more in women. Further studies are needed to identify the mechanisms and prognostic implications of this sex-related difference.
653 a Aged
653 a Aged
653 a 80 and over
653 a Antihypertensive Agents/*therapeutic use
653 a Atenolol/*therapeutic use
653 a Female
653 a Follow-Up Studies
653 a Heart Ventricles/ultrasonography
653 a Humans
653 a Hypertension/drug therapy
653 a Hypertrophy
653 a Left Ventricular/drug therapy/*ultrasonography
653 a Losartan/*therapeutic use
653 a Male
653 a Middle Aged
653 a Remission Induction
653 a *Sex Factors
653 a Time Factors
700a Palmieri, V.4 aut
700a Wachtell, K.4 aut
700a Liu, J. E.4 aut
700a Gerdts, E.4 aut
700a Nieminen, M. S.4 aut
700a Koren, M. J.4 aut
700a Zabalgoitia, M.4 aut
700a Wright, J. T.4 aut
700a Dahlöf, Björn,d 1953u Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute4 aut0 (Swepub:gu)xdahbj
700a Devereux, R. B.4 aut
710a Göteborgs universitetb Hjärt-kärlinstitutionen4 org
773t J Hum Hypertensg 18:6, s. 411-6q 18:6<411-6x 0950-9240
8564 8u https://gup.ub.gu.se/publication/56086

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy